Marshall Wace, LLP Clovis Oncology, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $235,074 - $638,058	223,880 Added 259.59%	310,123 $370,000
Q2 2022 Aug 15, 2022	BUY	$0.63 - $2.96 $54,333 - $255,279	86,243 New	86,243 $155,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $190,428 - $1.04 Million	-63,476 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $249,460 - $974,356	63,476 New	63,476 $249,000
Q1 2019 May 14, 2019	SELL	$17.66 - $30.28 $639,009 - $1.1 Million	-36,184 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $253,382 - $711,781	21,787 Added 151.33%	36,184 $650,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $422,839 - $712,363	14,397 New	14,397 $423,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $1.07 Million - $1.57 Million	-18,567 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $1.25 Million - $1.57 Million	18,567	18,567 $1.52 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.